Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Status Terminated

Clinical Trial Summary

This is a single-arm, phase I/II trial to determine the Maximum Tolerated Dose (MTD), Recommended Phase II Dose (RP2D), and the safety and efficacy of the combination of nivolumab-ipilimumab plus lurbinectedin in patients with relapsed/recurrent small cell lung cancer after progression with first-line, platinum-based chemotherapy

Clinical Trial Description

Study was originally designed as a Phase I/II but was terminated during the Phase I portion due to dose limiting toxicities. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04610658
Study type	Interventional
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact
Status	Terminated
Phase	Phase 1
Start date	November 23, 2020
Completion date	March 24, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05552846` - Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy	Phase 2
Terminated	`NCT04022876` - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)	Phase 1
Recruiting	`NCT06022757` - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)	Phase 1/Phase 2
Recruiting	`NCT04923776` - Liver Directed RT + Chemo-immunotherapy for ES-SCLC	Phase 2
Recruiting	`NCT04168281` - Watchful Observation of Patients With LD-SCLC Instead of the PCI	N/A
Completed	`NCT03239171` - Bioinformation Therapy for Lung Cancer	Phase 2/Phase 3
Recruiting	`NCT04539977` - PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer	Phase 2
Completed	`NCT03345485` - Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06103682` - LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)	N/A
Recruiting	`NCT04170946` - Talazoparib and Thoracic RT for ES-SCLC	Phase 1
Recruiting	`NCT03523234` - Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage	N/A
Recruiting	`NCT05620134` - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/Phase 2
Recruiting	`NCT05578326` - Study of Trilaciclib and Lurbinectidin	Phase 2
Recruiting	`NCT06255197` - Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Active, not recruiting	`NCT04116320` - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT05091567` - A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer	Phase 3
Terminated	`NCT04596033` - TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy	Phase 1
Recruiting	`NCT06160596` - Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Completed	`NCT03547804` - A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer	Phase 2